PAUL HOPPER – CHAIRMAN
Paul Hopper has international and ASX biotech capital markets experience and over 25 years’ experience in the medical, healthcare & life sciences sectors, particularly in immune-oncology and vaccines. He is the former Chairman of Viralytics Ltd (acquired by Merck for $500m in 2018), Founder and Director of Prescient Therapeutics Ltd, Founder of Imugene Ltd and Polynoma LLC, former Director of pSivida Corp, Somnomed Ltd and Fibrocell Science, Inc. Paul has deep experience in corporate governance, risk and strategy.
DAVID PHILLIPS – EXECUTIVE DIRECTOR
David Phillips joined the Board as a Non-Executive Director in April 2018. He has 30 years of experience in the global healthcare industry, including Glaxo Wellcome, Cephalon Inc, Oxford Molecular Group Plc and SR One (GlaxoSmithKline’s corporate venture fund). David spent 12 years at Board level as Chief Business Officer of Argenta Discovery, The Automation Partnership and BioFocus PLC. David re-joined GlaxoSmithKline’s (GSK) SR One corporate venture arm in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and in parallel investing in early-stage life science companies. David leads the Business Development activities.
DR DEBORA BARTON – NON-EXECUTIVE DIRECTOR
Dr Debora Barton brings more than 20 years of oncology experience, both in academia as a practicing physician and in the biotechnology/pharmaceutical industry. Dr Barton has served in key senior executive positions in cellular therapy and radiopharmaceutical biotech companies including Carisma Therapeutics where Dr Barton is currently the Chief Medical Officer, Iovance Biotherapeutics and Advanced Accelerator Applications, acquired by Novartis during Debora’s tenure. In her leadership roles, Debora built Clinical Development and Drug Safety teams setting up infrastructure for the conduct of clinical studies and was instrumental in obtaining FDA Breakthrough Designation for a cell therapy product and in the approval of a radiopharmaceutical agent by both FDA and EMA.
Previously, Debora spent 10 years at Celgene and Novartis, always focusing on improving the lives of cancer patients. She holds an MD from Pontificia Universidade Catolica Sao Paulo (PUC-SP) and completed her fellowship in Oncology at Federal University of Sao Paulo (UNIFESP) in Brazil.
DAVID SIMMONDS – NON-EXECUTIVE DIRECTOR
David was a senior audit partner with Ernst & Young from 1989 to 2017. From 2008 to 2013, David led the Capital Markets desk in Australia with responsibility for overseeing or reviewing all Australian cross border fundraisings. As an audit partner, David was involved in several high-profile businesses including Ramsay Health Care Ltd, John Fairfax Holdings and Commonwealth Bank of Australia and also was audit partner for the Australian operations of the leading US technology companies Hewlett Packard, Sun Microsystems and Oracle. David is currently a member of the Board and chairs the Audit, Risk and Finance Committee of MS Research Australia, the largest national not-for-profit body dedicated to funding and coordinating multiple sclerosis research in Australia.
DR MICHAEL BAKER – CEO AND MANAGING DIRECTOR
Dr Baker was an Investment Manager with the leading Australian life science fund, BioScience Managers, where he was responsible for deal sourcing from networks, conferences, universities and research institutes. He also conducted due diligence to shortlist investment opportunities and played an active role in managing portfolio companies. Michael was a senior manager at Hexima Limited which specialises in developing agricultural and pharmaceutical products.
Dr Baker has a PhD in Biochemistry and was also awarded the prestigious Nancy Millis award for the most outstanding thesis for the Faculty of Science, Technology and Engineering, 2010. He was an Alexander von Humboldt Research Fellow at the University of Cologne with nine publications, one in the prestigious journal Science. He was also awarded an MBA at Melbourne Business School, where he was included in the Dean’s Honours List for being in the top 10% of graduating students.